Leucovorin (folinic acid) is not a proven treatment for autism. There is some early research suggesting it may help a small subgroup of autistic children — particularly those with language difficulties and a specific folate transport problem — but the evidence is incomplete, the largest trial has been retracted, and neither UK nor US medical guidance recommends it for autism.
If you are a parent looking into this, you deserve an honest account of what the research actually shows. That is what this guide tries to provide.
Leucovorin is a reduced form of folate (vitamin B9). In mainstream medicine it has been used for decades, mainly to reduce side effects during certain chemotherapy treatments.
It is not the same as the folic acid tablets you buy in a health shop. Leucovorin is a prescription medicine. The form used in autism research is called d,l-leucovorin or calcium folinate.
Why does folate matter for brain development? Because folate plays a role in DNA synthesis, gene expression and neurotransmitter function. If folate is not reaching the brain properly, that could — in theory — affect language, attention and behaviour during early development.
The interest centres on something called folate receptor alpha autoantibodies (FRAAs). These are antibodies that may block folate from crossing the blood-brain barrier in the normal way.
Some studies have found that these antibodies are present in a surprisingly high proportion of autistic children studied — one review suggested around 70%. That is much higher than in the general population.
But this does not mean 70% of autistic children have a folate problem. The studies are small. The testing is not standardised. And finding antibodies in a blood test does not prove they are causing symptoms.
What it does suggest is that there may be a biologically distinct subgroup of autistic children where folate transport is disrupted. Leucovorin, because it uses a different route to get into the brain, might bypass that blockage. That is the hypothesis researchers are testing.
There have been five randomised controlled trials (RCTs) of leucovorin in autistic children. Here is what they found:
Frye et al. 2018 (USA) — 48 children with autism and language impairment. 12 weeks of high-dose folinic acid (2 mg/kg/day, up to 50 mg/day) versus placebo. The folinic acid group showed significantly greater improvement in verbal communication. The effect was strongest in children who tested positive for FRAAs. This is still the most-cited positive trial. (PubMed: 27752075)
EFFET trial 2020 (France) — A smaller pilot study from the University of Nancy. Reported improvement in overall autism severity scores (ADOS) with folinic acid compared to placebo over 12 weeks. No serious side effects were reported. (PubMed: 32387472)
2025 Chinese RCT — Reported that high-dose folinic acid may improve social reciprocity, with response linked to folate-metabolism gene variants (MTHFR polymorphisms). Published in Nutrients. (PubMed: 40362912)
Panda et al. 2024 (India) — This was the largest trial (77 children). It claimed positive results over 24 weeks. This study has been retracted. See the next section.
Earlier open-label studies — Several smaller, non-blinded studies reported improvements. These are considered weaker evidence because without a placebo control, it is impossible to separate genuine drug effects from natural development and placebo response.
In September 2024, a team led by Prateek Kumar Panda published a randomised, double-blind, placebo-controlled trial in the European Journal of Pediatrics. It included 77 autistic children and reported that 24 weeks of oral folinic acid significantly reduced autism symptom severity.
This trial became widely cited — including by US federal health officials when they announced expanded use of leucovorin for autism in late 2025.
In February 2026, the paper was retracted.
Researchers at Geisinger College of Health Sciences noticed that numbers in the data tables did not add up. They posted their concerns on PubPeer. The journal investigated, asked the authors for the original dataset, and could not replicate the published results. The retraction notice stated the editor "no longer has confidence in the validity of the results and conclusions."
One of the study authors described the issues as "unintentional statistical analysis errors."
This is where the story gets confusing — and where some online information is misleading.
In September 2025, the US Department of Health and Human Services announced that the FDA would expand leucovorin's use for autism, claiming it could benefit "hundreds of thousands" of children. This generated enormous parental interest and demand.
On 10 March 2026, the FDA approved leucovorin — but only for FOLR1-related cerebral folate transport deficiency (CFD-FOLR1). This is an ultra-rare genetic condition. Fewer than 50 cases have been identified worldwide. Some people with CFD-FOLR1 have developmental delays and autistic features, but this is a specific genetic diagnosis, not autism in general.
A senior FDA official stated clearly: "Right now we don't have sufficient data to say that we could establish efficacy for autism more broadly."
The American Academy of Pediatrics (AAP) also issued interim guidance in December 2025: it does not recommend leucovorin for autism and has no prescribing guidelines for this indication.
The Coalition of Autism Scientists reviewed the evidence in 2025 and concluded there was insufficient scientific evidence to establish leucovorin as a safe and effective autism treatment (MedPage Today, Feb 2026).
So whilst the headlines said "FDA approves leucovorin," the reality is much more limited. The approval is for an extremely rare genetic condition, not for autism.
If leucovorin helps anyone with autism, the evidence so far points towards a narrow subgroup:
The Frye trial is the clearest example: verbal communication improved more in the folinic acid group, and the improvement was most pronounced in FRAA-positive children.
This is important context. Online discussions often present leucovorin as a treatment for "autism" as a whole. The more honest version is that researchers are exploring whether it helps a specific biological subgroup — children whose folate transport into the brain appears to be disrupted. That is a much narrower claim.
There is currently no widely available, standardised FRAA blood test on the NHS. Some private laboratories offer it, but interpreting the results without specialist guidance is not straightforward.
In the published trials, leucovorin has generally been described as reasonably well tolerated. Reported side effects include:
The FDA's approval for CFD-FOLR1 also lists itching, rash, hives, breathing difficulty and — rarely — anaphylaxis as possible side effects.
NICE clinical guideline CG170 (last updated June 2021) is clear: medication should not be prescribed to treat the core features of autism in children and young people as routine care.
Leucovorin is not mentioned specifically in NICE guidance because it has not reached the evidence threshold to be considered. It is not an established NHS treatment for autism.
If leucovorin were to be considered for a child in the UK, it would need to be through a specialist clinician with a clear clinical rationale — such as confirmed or suspected cerebral folate deficiency — and with appropriate monitoring in place.
If you are considering leucovorin for your child, these questions may help you have a more informed conversation with their clinician:
Leucovorin is a real medicine with a real hypothesis behind it. The idea that some autistic children have a folate transport problem is biologically plausible and supported by early research.
But "plausible" and "proven" are very different things.
The largest trial has been retracted. The FDA approved leucovorin only for an ultra-rare genetic condition, explicitly stating there is not enough evidence for broader autism use. The AAP does not recommend it for autism. The Coalition of Autism Scientists found insufficient evidence. UK guidance does not support prescribing medication for core autism features.
What remains is a small body of research — mostly one 48-child trial from 2018 — suggesting a possible benefit for verbal communication in a subgroup of FRAA-positive children with language difficulties.
That is worth paying attention to. It is worth further research. But it is not enough to recommend leucovorin as a treatment for autism, and any source that presents it as a breakthrough or a cure is not giving you the full picture.
If you are considering it for your child, do so with a specialist clinician who understands the evidence, can test for the relevant biomarkers, and can monitor your child properly. Do not buy supplements online and hope for the best.
Your child deserves evidence-based care. So do you.
No. Folic acid is the synthetic form of folate found in supplements and fortified foods. Leucovorin (folinic acid) is a reduced, biologically active form that does not require the same enzymatic conversion. It also uses a different transport mechanism to enter the brain, which is why it is of interest in folate transport disorders. Leucovorin is a prescription medicine; folic acid is available over the counter.
No. Leucovorin is a prescription-only medicine in the UK. Some parents purchase folinic acid supplements online, but these are not the same formulation or dose used in research trials. Self-medicating with high-dose folinic acid without medical supervision is not recommended.
No. Leucovorin is not an established NHS treatment for autism. NICE guidance (CG170) does not recommend medication for the core features of autism. Any UK use of leucovorin for autism would be off-label and specialist-led.
FRAA stands for folate receptor alpha autoantibody. It is a blood test that checks for antibodies that may block folate transport into the brain. It is not routinely available on the NHS. Some private laboratories and specialist clinicians in the UK can arrange testing, but the test is not standardised and interpretation requires specialist knowledge.
There is an ongoing larger-scale double-blind, placebo-controlled trial (NCT02839915) led by Dr Richard Frye in the US, looking at leucovorin for language impairment in autistic children. UK-based trials are not currently listed on major registries, but it is worth checking ClinicalTrials.gov and asking your child's clinician about any emerging studies.
Disclaimer: SENDPath provides information for families navigating SEND in Kent and beyond. We are not clinicians. Nothing on this page constitutes medical advice. Always consult a qualified healthcare professional before making treatment decisions for your child.
Another drug/treatment evidence story — the GABA theory, Phase 3 results, and what the failure tells us about autism research.
Read guide →The NEJM trial, why early promise didn't translate, and what the evidence says now.
Read guide →A practical guide to what to do — and what not to do — after your child's diagnosis.
Read guide →An honest guide to stem cell therapy — what the research shows, the risks of unregulated clinics, and how to protect your family from exploitation.
Read guide →GFCF diets, probiotics, omega-3, vitamins, food selectivity and ARFID — an honest guide to what the evidence says.
Read guide →The latest research on peripheral sensory neurons — what it means for sensory difficulties and what families can do now.
Read guide →